Lenz Therapeutics, Inc

This phase 3 study tested the long-term safety of LNZ101 eye drops, a combination of aceclidine and brimonidine, in 362 adults aged 45-75 with presbyopia (age-related blurry near vision). Participants used the drops regularly and were monitored for side effects. The study is comp…

This study tested an eye drop called LNZ101 to help people with presbyopia (age-related trouble seeing up close) read without glasses. 469 adults aged 45-75 received the drops, and researchers measured how many gained clear near vision without losing distance vision on the first …

This Phase 3 trial tested LNZ101 eye drops in 229 people aged 45-75 with presbyopia, a condition that makes it hard to see up close. The drops combine aceclidine and brimonidine to temporarily improve near vision. The main goal was to see if participants could read three lines be…